Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion

Description

Summary

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1), in subjects with MM having progressed within one 18 months of initial treatment including autologous stem cell transplantation (ASCT) (Cohort 2a), and without ASCT (Cohort 2b) or, in subjects with inadequate response post ASCT during initial treatment (Cohort 2c) Approximately 181 subjects will be enrolled into one of two cohorts. Cohort 1 will enroll approximately 73 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2a will enroll approximately 39 MM subjects, with 1 prior anti-myeloma therapy including ASCT and with early relapse. Cohort 2b will enroll approximately 39 MM subjects with 1 prior anti-myeloma therapy not including ASCT and with early relapse. Cohort 2c will enroll approximately 30 MM subjects with inadequate response to ASCT during their initial anti-myeloma therapy. The cohorts will start in parallel and independently.

Official Title

A Phase 2, Multicohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)

Details

Anti-myeloma bridging treatment is allowed for disease control while bb2121 is being manufactured for cohorts 1, 2a and 2b only.

Keywords

Multiple Myeloma bb2121 Relapsed and Refractory Multiple Myeloma High Risk Multiple Myeloma Neoplasms, Plasma Cell

Eligibility

You can join if…

Open to people ages 18 years and up

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF)
  2. Subject has measurable disease, defined as:
  3. M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP ≥ 0.5 g/dL or uPEP ≥ 200 mg/24 hours and/or
  4. Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
  5. Subjects with one of the following cohort specific requirements:

Cohort 1 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens:

  • Subject must have received at least 3 prior anti-myeloma treatment regimens.

Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen

  • Subject must have undergone at least 2 consecutive cycles of treatment for each regimen, unless PD was the best response to the regimen
  • Subject must have received prior treatment with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody
  • Subject has evidence of PD on or within 60 days of the most recent prior treatment regimen
  • Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen

Cohort 2 subjects with 1 prior anti-myeloma treatment regimen:

  • Subject must have received only 1 prior anti-myeloma treatment regimen. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen
  • Subject must have the following HR factors:
  • R-ISS stage III AND
  • Early relapse defined as:

Cohort 2a: PD < 18 months since date of start of initial therapy. Initial therapy must contain induction, ASCT (single or tandem) and lenalidomide containing maintenance.

Cohort 2b: PD < 18 months since date of start or initial therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone Cohort 2c: Subject must have received minimum 3 cycles of induction therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone. Subjects must have had ASCT (single or tandem AND < VGPR (excluding PD) at first assessment between 70 to 110 days after last ASCT, with initial therapy without consolidation and maintenance.

  1. Subject must have Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  2. Subject must have recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy

You CAN'T join if...

The presence of any of the following will exclude a subject from enrollment:

  1. Subject used any investigational agents within 14 days of leukapheresis
  2. Subject received any of the following within the last 14 days of leukapheresis:
  3. Plasmapheresis
  4. Major surgery (as defined by the investigator)
  5. Radiation therapy other than local therapy for myeloma associated bone lesions
  6. Use of any systemic anti-myeloma drug therapy
  7. Subject with known central nervous system involvement with myeloma
  8. Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation
  9. History or presence of clinically relevant central nervous system (CNS) pathology
  10. Subject with active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or clinically significant amyloidosis
  11. Inadequate organ function Subject with a history of Class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to starting study treatment
  12. Ongoing treatment with chronic immunosuppressants
  13. Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy
  14. . Subject has received ASCT within 12 weeks prior to leukapheresis
  15. . Subject has history of primary immunodeficiency
  16. . Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B or active hepatitis A or C
  17. . Subject has uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
  18. . Subject with prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years
  19. . Pregnant or lactating women
  20. . Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab

Locations

  • UCSF Medical Center accepting new patients
    San Francisco California 94142 United States
  • Mayo Clinic Arizona accepting new patients
    Scottsdale Arizona 85259 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Celgene
ID
NCT03601078
Phase
Phase 2
Study Type
Interventional
Last Updated